Farther Finance Advisors LLC Buys 11,557 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Farther Finance Advisors LLC lifted its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 88.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,599 shares of the company’s stock after purchasing an additional 11,557 shares during the quarter. Farther Finance Advisors LLC’s holdings in MiMedx Group were worth $145,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. ProShare Advisors LLC increased its holdings in shares of MiMedx Group by 8.5% during the first quarter. ProShare Advisors LLC now owns 20,735 shares of the company’s stock valued at $160,000 after acquiring an additional 1,631 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in MiMedx Group by 1.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company’s stock valued at $1,082,000 after purchasing an additional 1,822 shares during the period. Hsbc Holdings PLC increased its stake in MiMedx Group by 7.3% during the 2nd quarter. Hsbc Holdings PLC now owns 34,343 shares of the company’s stock valued at $233,000 after purchasing an additional 2,329 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in MiMedx Group by 7.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,623 shares of the company’s stock valued at $316,000 after purchasing an additional 3,222 shares in the last quarter. Finally, Marshall Wace LLP raised its holdings in MiMedx Group by 1.1% during the second quarter. Marshall Wace LLP now owns 298,818 shares of the company’s stock worth $2,071,000 after buying an additional 3,223 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MDXG. Craig Hallum dropped their price target on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Price Performance

Shares of NASDAQ:MDXG opened at $7.53 on Monday. The company has a market capitalization of $1.11 billion, a P/E ratio of 13.69 and a beta of 1.94. The company’s 50-day moving average is $6.13 and its 200 day moving average is $6.71. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.27.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.